Lynavoy GlaxoSmithKline Trading Services Limited · Opinion · ATC A05AX
Therapeutic indication (EMA)
Treatment of cholestatic pruritus in adult patients with primary biliary cholangitis.
Active substance
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| LYNAVOY | 40MG | tablet · oral | INTERCEPT | Prescription | 17 Mar 2026 |
Treatment of cholestatic pruritus in adult patients with primary biliary cholangitis.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.